Skip to content
Screener

Aquestive Therapeutics, Inc. AQST Manufacture and supply revenue — Revenue

Other product segments

License and royalty revenue (a)
$1.33M+58.0%
Co-development and research fees
$582K+54.0%
Proprietary product revenue, net
$0

Similar metrics at other companies

Builders FirstSource logo
BLDRManufactured Products — Revenue
$831.62M-12.7%
Metallus logo
MTUSManufactured Components — Revenue
$69.7M-11.4%
Sutro Biopharma logo
STROMaterials Supply — Revenue
$1.08M-41.4%
Alkermes logo
ALKSManufactured Product And Royalty — Revenue
$84.29M+1.0%
ARS Pharmaceuticals, Inc. logo
SPRYRevenue Under Supply Agreements — Revenue
$2.74M
RVL
RVLVManufactured Product Other — Revenue
$3.8M+29.1%

Other financials

Income statement

See full
Revenue$13.8M+38.1%
Gross profit$9.8M+80.1%
Operating income-$8.2M+27.7%
Net income-$22.9M-68.8%
EPS (diluted)-$0.18-28.6%

Balance sheet

See full
Cash & equivalents$98.5M+62.7%
Total debt$63.4M+6.0%
Total equity-$56.6M+22.0%
Total assets$132.1M+41.0%

Cash flow

See full
Operating cash flow-$9.4M-19.3%
CapEx$212.0K+98.1%
Free cash flow-$9.7M-20.3%

Valuation

See full
Market cap$494.34M+28.9%
Enterprise value$459.23M+20.0%
P/S9.1×+0.5×

Profitability

See full
Gross margin67%+5.9pp
Operating margin-97.5%-15.0pp
Net margin-144.6%-2.6pp
FCF margin-85%-17.0pp

Returns & leverage

See full
Return on equity121.1%
Debt / equity-1.1×
Current ratio7.2×+3.7×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:10 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001398733-26-000042
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Manufacture and supply revenue$11,911$9,583$20,704$16,776
License and royalty revenue (a)1,3268396,7211,629
Co-development and research fees582378840796
Proprietary product revenue, net(797)(478)
Total revenues$13,819$10,003$28,265$18,723

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Aquestive Therapeutics, Inc.'s manufacture and supply revenue — revenue?
Aquestive Therapeutics, Inc. (AQST) reported manufacture and supply revenue — revenue of $11.91M in Q2 2026.
How has Aquestive Therapeutics, Inc.'s manufacture and supply revenue — revenue changed year-over-year?
Aquestive Therapeutics, Inc.'s manufacture and supply revenue — revenue increased by 24.3% year-over-year, from $9.58M to $11.91M.
What is the long-term trend for Aquestive Therapeutics, Inc.'s manufacture and supply revenue — revenue?
Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s manufacture and supply revenue — revenue has grown at a 3.3% compound annual growth rate (CAGR), from $35.31M to $40.23M.
What does manufacture and supply revenue — revenue mean?
This metric represents the total gross revenue recognized from the manufacturing and supply of pharmaceutical products to third-party partners or customers. It reflects the company's ability to monetize its proprietary drug delivery platforms and manufacturing capabilities through contract manufacturing services. This revenue stream is a key indicator of the company's operational scale and its success in leveraging production infrastructure to support commercialized products.

Ask your AI about Aquestive Therapeutics, Inc.'s manufacture and supply revenue — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude